Picture of Giant Biogene Holding Co logo

2367 Giant Biogene Holding Co Cashflow Statement

0.000.00%
hk flag iconLast trade - 00:00
Consumer DefensivesSpeculativeLarge CapHigh Flyer

Annual cashflow statement for Giant Biogene Holding Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:PROSPECTUSPROSPECTUSPROSPECTUSARSARS
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line6779739731,1781,745
Depreciation
Amortisation
Non-Cash Items-10.1-165-28.331.7-52.5
Unusual Items
Other Non-Cash Items
Changes in Working Capital-28.34.64-275-305-79.3
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities6568346929321,647
Capital Expenditures-1,606-5,161-4,036-2,352-228
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items1,0164,6405,6001,494-299
Sale of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Sale of Intangible Assets
Other Investing Cash Flow
Cash from Investing Activities-590-5211,563-859-527
Financing Cash Flow Items-2.16-17.5-2,619-379-3.54
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities-2.16-17.54,476-5,79051.8
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash64.42956,735-5,7721,173